OrthoPediatrics surges 6% on first positive cash flow, margin expansion
Pediatric orthopedic device maker achieves profitability milestone as Q4 revenue jumps 17% year-over-year
OrthoPediatrics Corp. shares surged 6.4% on Thursday after the pediatric orthopedic device maker reported its first-ever positive free cash flow and delivered strong fourth-quarter results that underscore the company's momentum in a niche healthcare market.
The Warsaw, Indiana-based company generated $9.8 million in free cash flow during the fourth quarter of 2025, marking a significant milestone for a business that has historically operated with negative cash flow. The achievement came alongside a 17% year-over-year increase in quarterly revenue to $61.6 million, according to the company's 8-K regulatory filing.
"We achieved several important milestones in the fourth quarter, including our first quarter of positive free cash flow in the company's history," the company stated in its earnings announcement.
The company's profitability metrics showed marked improvement. Adjusted EBITDA swung to positive territory at $4.8 million, compared to $3.0 million in the prior-year period. Gross margin expanded substantially to 73.2% from 67.5%, reflecting operational efficiencies and favorable product mix.
For the full year 2025, OrthoPediatrics delivered record revenue of $236.3 million, representing 15% growth compared to the prior year. Operating cash flow improved by $22 million over the full year, demonstrating strengthening operational performance.
The quarterly results came in slightly below analyst expectations on both revenue and earnings per share. Revenue of $61.6 million missed the consensus estimate of $62.3 million by 1.1%, while the company reported an adjusted loss per share of $0.26. However, investors focused on the improving fundamental metrics rather than the modest earnings miss, driving the stock to $17.79 in afternoon trading.
Looking ahead, OrthoPediatrics reaffirmed its guidance for fiscal 2026, projecting revenue of $262 million to $266 million, representing 11% to 13% growth. The company expects adjusted EBITDA of $25 million and free cash flow to reach breakeven, suggesting the business is approaching sustainable profitability.
The stock's positive reaction Thursday extends what has been a volatile year for shares of OrthoPediatrics, which currently trade below their 200-day moving average of $19.29 but have recovered from a 52-week low of $15.28 reached earlier this year. The 52-week high stands at $26.40.
Analysts remain broadly optimistic about the company's prospects. The consensus price target sits at $24.00, representing roughly 35% upside from current levels. Of the eight analysts covering the stock, seven have buy ratings (three strong buys and four buys) while one rates it a hold, according to market data.
OrthoPediatrics specializes in developing orthopedic implants and devices specifically designed for children, addressing a market segment often overlooked by larger medical device companies focused on adult patients. The company's product portfolio includes solutions for trauma reconstruction, spinal deformity correction, and sports medicine procedures tailored to pediatric anatomy.
The achievement of positive free cash flow is particularly noteworthy for investors, as it demonstrates the company's ability to self-fund growth without relying on external capital. This milestone could improve OrthoPediatrics' standing with institutional investors, who currently own approximately 68% of outstanding shares. Insiders retain a significant 33% stake, indicating management's continued confidence in the business trajectory.
The healthcare technology sector has faced pressure in recent months amid broader market volatility and regulatory scrutiny, but OrthoPediatrics' specialized focus on pediatric orthopedics provides some insulation from competitive pressures in larger adult orthopedic markets. The company's ability to expand margins while growing revenue suggests it's gaining operational leverage as it scales.